发明名称 |
MEANS FOR TREATING PROSTATE HYPERTROPHY AND PROSTATE CANCER |
摘要 |
<p>A regime for therapeutic management of a benign prostatic hyperplasia and prostatic cancer employs Cetrorelix alone or in combination with alpha -reductase inhibitors or alpha -receptor blocking agents. The regimen reduces the volume of the prostate and avoids the side effects associated with testosterone levels being in a castration range. Cetrorelix is administered at dosages between 0,5 mg/day and 20 mg/week or about 0.014 mg/kg body weight per day to 0,30 mg/kg body weight per week or at levels of about 25 to 120 mg of Cetrorelix per month or 0.376 mg/kg to 1.71 mg/kg per month. Cetrorelix can be administered with alpha -reductase inhibitors or alpha -receptor blocking agents.</p> |
申请公布号 |
HU0000261(A3) |
申请公布日期 |
2001.03.28 |
申请号 |
HU20000000261 |
申请日期 |
1997.09.01 |
申请人 |
ZENTARIS GMBH, FRANKFURT AM MAIN |
发明人 |
|
分类号 |
A61P5/24;A61K31/495;A61K38/04;A61K38/09;A61K45/00;A61K45/06;A61P13/08;A61P35/00 |
主分类号 |
A61P5/24 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|